Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1167 in advanced solid tumors
NCT05473624Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M9466 in solid tumor (advanced stage), ovarian cancer, breast cancer and 2 more, sponsored by Hengrui. Primary endpoints: Dose-limiting toxicity up to 24 days, Maximum tolerated dose up to 24 months and 2 more. Started Aug 2022; status: recruiting.
02
Drugs
M9466
03
Conditions
solid tumor (advanced stage)ovarian cancerbreast cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05473624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473624.